Medical Cannabis and Autism: What a Small Study Found About Quality of Life

Could carefully supervised cannabis-based treatment help some autistic people with difficulties such as sleep, distress, seizures or everyday functioning? A small Brazilian study raised some interesting questions—and the results deserve a closer look.

Why we’re looking at this research

At Paradise Compassion Club, we believe patients and families deserve to understand the research, not just read a promising headline. When I came across a report about medical cannabis and autism, I wanted to know what the researchers actually did, what families noticed, and what the study cannot yet prove.

Autism spectrum disorder (ASD) is a lifelong neurodevelopmental difference. Autistic people have a wide range of strengths, experiences and support needs. Autism itself is not something that needs to be “cured.” The medical question here is narrower: can a treatment help certain associated difficulties that affect comfort, health or quality of life?

What did the researchers do?

The original study was published in Frontiers in Psychiatry in August 2023 by researchers in Brazil. It looked back at the experiences of 20 autistic patients who received full-spectrum cannabis extracts under medical supervision. These extracts contained cannabidiol (CBD) and, in some cases, tetrahydrocannabinol (THC).

Instead of giving everybody an identical product, clinicians adjusted the formulation and dose according to each person’s response. Eighteen patients began with CBD-rich extracts; three of those later added small amounts of a THC-rich extract. Two others used a combination of CBD-rich and THC-rich extracts throughout treatment. Most patients were treated for at least six months.

This was a retrospective observational study. That means researchers reviewed treatment experiences and asked patients or caregivers about changes. It was not a randomized trial, and there was no placebo group for comparison. That’s an important distinction.

What improvements did families report?

Caregivers reported changes in several areas that can make daily life more challenging for some autistic people. Among those who had the relevant difficulty at the start, reported improvements included:

Seizures: 84% of the six patients with seizures were reported to improve.
Episodes of intense distress or meltdowns: 76% of 17 affected patients were reported to improve.
Discomfort in noisy or crowded places: 72% of 14 affected patients were reported to improve.
Aggression toward others: 67% of 12 affected patients were reported to improve.
Attention to spoken communication: 85% of the 20 participants were reported to improve.

Those percentages sound impressive, but notice how small the groups were. For example, the seizure figure is based on only six people. One person’s experience can change a percentage considerably in a study this small.

What about quality of life?

For me, this is the part of the research worth discussing. The investigators reported that caregivers perceived improvement in patients’ quality of life in 19 of the 20 cases. They also reported better family quality of life in many cases.

That might mean a household finding it easier to manage distressing situations, a person sleeping better, or a family enjoying outings with less discomfort. These are meaningful goals. But we need to remember that the findings came mainly from caregiver questionnaires rather than blinded, independently measured outcomes.

Did everyone benefit?

No. Some participants had no improvement, and some symptoms became worse. The paper reported agitation in six patients, difficulty sleeping in three and other effects including appetite or weight changes. One participant stopped treatment because symptoms worsened.

That’s why it’s misleading to say medical cannabis is harmless or works the same way for everyone. CBD and THC can affect people differently, interact with other medications, and raise special safety questions in children and adolescents.

What does “full-spectrum” mean?

A full-spectrum extract contains multiple compounds from the cannabis plant rather than a single isolated cannabinoid. The products used in this study were medically supervised preparations, with formulations adjusted individually. The findings cannot be assumed to apply to any cannabis flower, edible, oil or product sold elsewhere.

The study also does not establish an ideal CBD-to-THC ratio or a safe dose for autistic patients. Those are questions that need carefully controlled research, particularly when young people are involved.

What has other research found?

A separate randomized, placebo-controlled study involving 150 autistic children and young adults, published in 2021, found some encouraging signals for particular measures of disruptive behaviour and social responsiveness, but not every primary or secondary measure improved. This illustrates why researchers look across multiple trials instead of treating one positive report as the final answer.

More recently, a 2025 systematic review concluded that evidence for cannabis-derived treatments in autism remained low or very low certainty overall. There are promising findings, but there is not yet enough reliable evidence to recommend cannabis as a general treatment for autism.

What I take away from this study

I think this research is worth sharing because it focuses on something families care about: quality of life. If a person is struggling with sleep, seizures, severe distress or other associated health problems, finding better ways to support them matters.

At the same time, a 20-person study without a control group cannot tell us that cannabis caused the improvements. It certainly doesn’t mean cannabis “treats autism” as a whole, or that families should try it on their own. The most responsible conclusion is that the findings justify more rigorous studies with clear safety monitoring.

Medical decisions, especially for children and for people taking other medicines, should be made with qualified healthcare professionals familiar with the person’s individual needs.